Sandbox:Sahar: Difference between revisions
No edit summary |
No edit summary |
||
Line 97: | Line 97: | ||
clinical features. | clinical features. | ||
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | | style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | ||
| style="padding: 5px 5px; background: # | | style="padding: 5px 5px; background: #0000CD;" align="center" |'''B''' | ||
| | | | ||
|- | |- | ||
Line 112: | Line 112: | ||
clinical probability. | clinical probability. | ||
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa''' | | style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa''' | ||
| style="padding: 5px 5px; background: # | | style="padding: 5px 5px; background: #0000CD;" align="center" |'''B''' | ||
| | | | ||
|- | |- | ||
Line 125: | Line 125: | ||
diagnosis. | diagnosis. | ||
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa''' | | style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa''' | ||
| style="padding: 5px 5px; background: # | | style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | ||
| | | | ||
|- | |- | ||
Line 138: | Line 138: | ||
tests should be considered. | tests should be considered. | ||
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa''' | | style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa''' | ||
| style="padding: 5px 5px; background: # | | style="padding: 5px 5px; background: #0000CD;" align="center" |'''B''' | ||
| | | | ||
|- | |- | ||
Line 149: | Line 149: | ||
recommended. | recommended. | ||
| style="padding: 5px 5px; background: #F08080;" align="center" |'''III''' | | style="padding: 5px 5px; background: #F08080;" align="center" |'''III''' | ||
| style="padding: 5px 5px; background: # | | style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | ||
| | | | ||
|- | |- | ||
Line 158: | Line 158: | ||
initial imaging investigation. | initial imaging investigation. | ||
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | | style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | ||
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | |||
! | ! | ||
|- | |- | ||
Line 176: | Line 176: | ||
!TOE | !TOE | ||
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | | style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | ||
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | |||
! | ! | ||
|- | |- | ||
!CT | !CT | ||
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | | style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | ||
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | |||
! | ! | ||
|- | |- | ||
Line 201: | Line 201: | ||
!CT | !CT | ||
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | | style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | ||
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | |||
! | ! | ||
|- | |- | ||
!MRI | !MRI | ||
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | | style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | ||
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | |||
! | ! | ||
|- | |- | ||
!TOE | !TOE | ||
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa''' | | style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa''' | ||
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | |||
! | ! | ||
|- | |- | ||
Line 224: | Line 224: | ||
recommended. | recommended. | ||
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | | style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | ||
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | |||
! | ! | ||
|- | |- | ||
Line 233: | Line 233: | ||
clinical probability of AAS. | clinical probability of AAS. | ||
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIb''' | | style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIb''' | ||
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | |||
! | ! | ||
|- | |- | ||
Line 246: | Line 246: | ||
recommended. | recommended. | ||
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | | style="padding: 5px 5px; background: #90EE90;" align="center" |'''I''' | ||
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C''' | |||
! | ! | ||
|} | |} |
Revision as of 04:06, 25 December 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recomendacations | Class | Level | References |
---|---|---|---|
History and clinical assessment | |||
In all patients with suspected
AAS, pre-test probability assessment is recommended, according to the patient’s condition, symptoms, and clinical features. |
I | B | |
Laboratory testing | |||
In case of suspicion of AAS,
the interpretation of biomarkers should always be considered along with the pretest clinical probability. |
IIa | B | |
In case of low clinical
probability of AAS, negative D-dimer levels should be considered as ruling out the diagnosis. |
IIa | C | |
In case of intermediate clinical
probability of AAS with a positive (point-of-care) D-dimer test, further imaging tests should be considered. |
IIa | B | |
In patients with high probability
(risk score 2 or 3) of AD, testing of D-dimers is not recommended. |
III | C | |
Imaging | |||
TTE is recommended as an
initial imaging investigation. |
I | C | |
In unstabled patients with a
suspicion of AAS, the following imaging modalities are recommended according to local availability and expertise: |
|||
TOE | I | C | |
CT | I | C | |
In stable patients with a
suspicion of AAS, the following imaging modalities are recommended (or should be considered) according to local availability and expertise: |
|||
CT | I | C | |
MRI | I | C | |
TOE | IIa | C | |
In case of initially negative
imaging with the persistence of suspicion of AAS, repetitive imaging (CT or MRI) is recommended. |
I | C | |
Chest X-ray maybe
considered in cases of low clinical probability of AAS. |
IIb | C | |
In case of uncomplicated
Type B AD treated medically, repeated imaging (CT or MRI)e during the first days is recommended. |
I | C |